A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma

We conducted a prospective phase I study to evaluate safety of an orally administered Salmonella encoding IL‐2 (SalpIL2) in combination with amputation and adjuvant doxorubicin for canine appendicular osteosarcoma. Efficacy was assessed as a secondary measure. The first dose of SalpIL2 was administe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritz, Sara E., Henson, Michael S., Greengard, Emily, Winter, Amber L., Stuebner, Kathleen M., Yoon, Una, Wilk, Vicki L., Borgatti, Antonella, Augustin, Lance B., Modiano, Jaime F., Saltzman, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645873/
https://www.ncbi.nlm.nih.gov/pubmed/29067193
http://dx.doi.org/10.1002/vms3.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645873/
https://www.ncbi.nlm.nih.gov/pubmed/29067193
http://dx.doi.org/10.1002/vms3.32

Ejemplares similares